Therapeutic effect of vidarabine monophosphate in the treatment of bronchiolitis
Objective To explore therapeutic effect of vidarabine monophosphate on children with bronchiolitis.Methods 122 children with bronchiolitis were selected and randomly divided into the observation group and the control group according to the order of admission,with 61 cases in each group.The control group received budesonide suspension for inhalation and compound ipratropium bromide solution for inhalation,while the observation group received vidarabine monophosphate for injection on the basis of the treatment of the control group.Both groups were treated for 7 days.The curative effects of two groups were observed after 7 days of treatment.The changes of the levels of clinical indexes of two groups were recorded.The lung function indexes,levels of serum amyloid A(SAA),leukotriene E4(LTE4)and monocyte chemoattractant protein-1(MCP-1)before treatment and after 7 days of treatment,and incidence of adverse reactions during treatment between two groups were compared.Results After 7 days of treatment,the total effective rate in the observation group(93.44％,57/61)was higher than that in the control group(80.33％,49/61)(P＜0.05).Wheezer,moist rales,cough disappearance time,and hospital stay in the observation group were shorter than those in the control group(P＜0.05).After 7 days of treatment,levels of time to peak tidal expiratory flow as a proportion of expiratory time(TPTEF/TE),and tidal volume(TV)in both grups were higher than those before treatment,and the observation group was higher than the control group;Levels of serum SAA,LTE4 and MCP-1,and inspiration time/expiratory time(TI/TE)in both grups were lower than those before treatment,and the observation group was lower than the control group(P＜0.05).During the treatment,there was no statistically significant difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion After treatment with budesonide and compound ipratropium bromide,combined treatment with vidarabine monophosphate can reduce the levels of serum SAA,LTE4 and MCP-1,and significantly improve lung function and clinical symptoms in children with bronchiolitis.This therapy can improve efficacy,shorten hospitalization time,and has good safety.
bronchiolitisvidarabine monophosphatelung functionserum amyloid protein Aleukotriene E4monocyte chemoattractant protein-1
万方数据
维普
